Dacomitinib(Vizimpro)

Another Name达克替尼、达可替尼、多泽润、DacoMitinib、Dacoplice、 PF299804

IndicationsThe first-line treatment for metastatic non-small cell lung cancer with epidermal growth factor receptor (EGFR) exon 19 deletion or exon 21L858R substitution mutation.